ASP 3026

Drug Profile

ASP 3026

Alternative Names: ASP-3026

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B cell lymphoma; Solid tumours

Most Recent Events

  • 31 Mar 2016 Astellas Pharma completes a phase I trial for Solid tumours & B-cell lymphoma in USA (NCT01284192)
  • 03 Feb 2014 Discontinued - Phase-I for B-cell lymphoma in USA (PO)
  • 03 Feb 2014 Discontinued - Phase-I for Solid tumours in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top